乾癬性関節炎治療の世界市場レポート 2025年

乾癬性関節炎治療市場規模は、今後数年間で力強い成長が見込まれます。2029年には171億6,000万米ドルに成長し、CAGRは9.4%となります。予測期間の成長は、個別化医療、新興の生物製剤と低分子製剤、治療選択肢の拡大、世界の高齢化に起因しています。予測期間における主な動向には、生物学的製剤、経口低分子化合物、特定の経路を標的とした治療、遠隔医療と遠隔モニタリング、患者中心の医療、実世界でのエビデンスなどの進歩が含まれます。

乾癬および乾癬性関節炎の有病率の増加は、乾癬性関節炎治療市場の拡大に大きく寄与しています。乾癬（PSO）と乾癬性関節炎（PsA）は、健康と生活の質に深刻な影響を与える炎症性疾患です。乾癬患者の約30％は乾癬性関節炎も経験しています。例えば、2024年1月、米国政府機関である国立医学図書館からの報告によると、乾癬患者における乾癬性関節炎の年間発症率は、患者100人あたり1.9％から2.7％です。時間の経過とともにPsAの発症リスクは顕著に増加し、発症率は乾癬診断後5年で1.7%、10年で3.1%、30年で20.5%に達します。したがって、乾癬と乾癬性関節炎の罹患率の上昇は市場成長の主要な促進要因です。

ヘルスケア支出の急増が乾癬性関節炎治療市場の成長を促進しています。医療費の増加は、関節症性乾癬のような診断を確定するために不可欠な診察、検査室検査、画像検査を含む様々な診断手順をサポートしています。例えば英国では、2022年のヘルスケア支出は約3,477億4,000万米ドルに達し、前年比0.7%の名目増加を示しています。このようなヘルスケア資源への投資の増加は、関節症性乾癬のような症状の治療の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界乾癬性関節炎治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の乾癬性関節炎治療市場：成長率分析
• 世界の乾癬性関節炎治療市場の実績：規模と成長, 2019-2024
• 世界の乾癬性関節炎治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界乾癬性関節炎治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の乾癬性関節炎治療市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非ステロイド性抗炎症薬（NSAID）
• 疾患修飾抗リウマチ薬（DMARDS）
• 生物学的製剤
• その他の薬物クラス
• 世界の乾癬性関節炎治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• トピック
• 世界の乾癬性関節炎治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の乾癬性関節炎治療市場非ステロイド性抗炎症薬（NSAIDs）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来のNSAIDs
• COX-2阻害剤
• 世界の乾癬性関節炎治療市場疾患修飾性抗リウマチ薬（DMARD）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来のDMARD
• 標的合成DMARD
• 世界の乾癬性関節炎治療市場、生物製剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍壊死因子（TNF）阻害剤
• インターロイキン阻害剤
• その他の生物学的製剤
• 世界の乾癬性関節炎治療市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 局所治療
• ヤヌスキナーゼ（JAK）阻害剤

第7章 地域別・国別分析

• 世界の乾癬性関節炎治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の乾癬性関節炎治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 乾癬性関節炎治療市場：競合情勢
• 乾癬性関節炎治療市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Astellas BioPharma K.K. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis International AG
• Eli Lilly and Company
• Pfizer Inc.
• CB Biosciences Inc.
• Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AstraZeneca plc
• Sanofi SA
• Otsuka Pharmaceutical Co. Ltd.
• Sumitomo Dainippon Pharma Co. Ltd.
• Bayer AG
• Abbott Laboratories
• Eisai Inc.
• Janssen Pharmaceuticals Inc.
• Bausch Health Companies Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 乾癬性関節炎治療市場2029：新たな機会を提供する国
• 乾癬性関節炎治療市場2029：新たな機会を提供するセグメント
• 乾癬性関節炎治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Psoriatic arthritis treatment aims to mitigate or halt the progression of a chronic inflammatory condition affecting joints and the areas where tendons and ligaments attach to bones (entheses). This treatment regimen concentrates on managing skin involvement, alleviating joint pain, and addressing associated disability.

The primary classes of drugs used in psoriatic arthritis treatment encompass nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologics, and other medications. Biologic medicines, a subset of treatment options, are substances derived from or containing components of living organisms. These medications can be administered through various routes, including oral, parenteral (injection or infusion), and topical applications. They are distributed through diverse channels such as hospital pharmacies, retail pharmacies, and online pharmacies to cater to the needs of patients undergoing psoriatic arthritis treatment.

The psoriatic arthritis treatment market research report is one of a series of new reports from The Business Research Company that provides psoriatic arthritis treatment market statistics, including global market size, regional shares, competitors with a psoriatic arthritis treatment market share, detailed psoriatic arthritis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the psoriatic arthritis treatment industry. This psoriatic arthritis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The psoriatic arthritis treatment market size has grown strongly in recent years. It will grow from $10.93 billion in 2024 to $12 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increased diagnosis, rising prevalence of psoriatic arthritis, increasing awareness of psoriatic arthritis and its treatments, expanding range of approved psoriatic arthritis treatments, government support for research and development, increased investment from pharmaceutical companies.

The psoriatic arthritis treatment market size is expected to see strong growth in the next few years. It will grow to $17.16 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to personalized medicine, emerging biologics and small molecules, expanding treatment options, global aging population. Major trends in the forecast period include advancements in biologics, oral small molecules, targeting specific pathways, telemedicine and remote monitoring, patient-centered care, and real-world evidence.

The growing prevalence of psoriasis and psoriatic arthritis has significantly contributed to the expansion of the psoriatic arthritis treatment market. Psoriasis (PSO) and psoriatic arthritis (PsA) are inflammatory conditions that can severely affect health and quality of life. Approximately 30% of individuals with psoriasis also experience psoriatic arthritis. For example, in January 2024, reports from the National Library of Medicine, a US government agency, indicated that the annual incidence of psoriatic arthritis among patients with psoriasis ranges from 1.9% to 2.7% per 100 patients. Over time, the risk of developing PsA increases notably, with incidence rates of 1.7% at five years, 3.1% at ten years, and reaching as high as 20.5% at thirty years after a psoriasis diagnosis. Therefore, the rising incidence of psoriasis and psoriatic arthritis is a key driver of market growth.

The surge in healthcare spending has propelled the growth of the psoriatic arthritis treatment market. Increased healthcare expenditure supports various diagnostic procedures, including medical appointments, laboratory tests, and imaging studies essential for confirming diagnoses like psoriatic arthritis. For instance, in the UK, healthcare spending reached around $347.74 billion in 2022, demonstrating a 0.7% nominal increase from the previous year. This increased investment in healthcare resources contributes to the growth of treatments for conditions like psoriatic arthritis.

Leading companies in the psoriatic arthritis treatment market are increasingly concentrating on developing advanced products, such as targeted biologic therapies, to provide more effective and personalized treatment options. These therapies aim to address the underlying inflammatory processes, improve patient outcomes, and enhance the overall quality of life for individuals living with this chronic condition. Targeted biologic therapy involves using specially designed drugs or substances that interfere with specific molecules involved in the growth and spread of disease, aiming to minimize damage to normal cells while maximizing therapeutic efficacy. For example, in January 2022, AbbVie, a US-based biopharmaceutical company engaged in discovering and developing medicines, announced that the U.S. Food and Drug Administration (FDA) had approved SKYRIZI (risankizumab-rzaa). SKYRIZI is an interleukin-23 inhibitor specifically indicated for the treatment of active psoriatic arthritis, targeting inflammation at its source by blocking the p19 subunit of IL-23. Clinical studies have shown significant improvements in joint symptoms and overall disease activity, with many patients achieving clinical remission and enhanced quality of life. Administered through subcutaneous injection, this therapy provides a convenient option for patients, allowing for flexible dosing schedules tailored to their individual needs.

Major pharmaceutical companies have also been instrumental in market growth by introducing new drugs like Cosentyx. This drug, developed by Novartis, is an interleukin-17A antagonist used to treat various autoimmune diseases, including psoriatic arthritis. In October 2023, its approval by the FDA marked a significant milestone, offering relief for symptoms like joint pain and skin problems associated with psoriatic arthritis.

In February 2023, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company acquired Nimbus Therapeutics for an undisclosed amount. The acquisition is anticipated to improve Takeda Pharmaceutical's position in the market for psoriatic arthritis treatments and broaden its product line. Nimbus Therapeutics is a US-based biotechnology company. It develops drugs for psoriatic arthritis treatment.

Major companies operating in the psoriatic arthritis treatment market include AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., CB Biosciences Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Abbott Laboratories, Eisai Inc., Janssen Pharmaceuticals Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, LEO Pharma A/S, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.

North America was the largest region in the psoriatic arthritis treatment market in 2024. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the psoriatic arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The psoriatic arthritis treatment market includes revenues earned by entities by reducing pain and swelling and controlling inflammation and pain. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Psoriatic Arthritis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on psoriatic arthritis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for psoriatic arthritis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The psoriatic arthritis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS); Disease-Modifying Anti-Rheumatic Drugs (DMARDS); Biologics; Other Drug Classes
• 2) By Route Of Administration: Oral; Parenteral; Topical
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs; COX-2 Inhibitors
• 2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs; Targeted Synthetic DMARDs
• 3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin Inhibitors; Other Biologics
• 4) By Other Drug Classes: Corticosteroids; Topical Treatments; Janus Kinase (JAK) Inhibitors
• Companies Mentioned: AbbVie Inc.; Amgen Astellas BioPharma K.K.; Johnson & Johnson Services Inc.; Bristol-Myers Squibb Company; Celgene Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Psoriatic Arthritis Treatment Market Characteristics

3. Psoriatic Arthritis Treatment Market Trends And Strategies

4. Psoriatic Arthritis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Psoriatic Arthritis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Psoriatic Arthritis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Psoriatic Arthritis Treatment Market Growth Rate Analysis
• 5.4. Global Psoriatic Arthritis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Psoriatic Arthritis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Psoriatic Arthritis Treatment Total Addressable Market (TAM)

6. Psoriatic Arthritis Treatment Market Segmentation

• 6.1. Global Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
• Disease-Modifying Anti-Rheumatic Drugs (DMARDS)
• Biologics
• Other Drug Classes
• 6.2. Global Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Topical
• 6.3. Global Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Psoriatic Arthritis Treatment Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Traditional NSAIDs
• COX-2 Inhibitors
• 6.5. Global Psoriatic Arthritis Treatment Market, Sub-Segmentation Of Disease-Modifying Anti-Rheumatic Drugs (DMARDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional DMARDs
• Targeted Synthetic DMARDs
• 6.6. Global Psoriatic Arthritis Treatment Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Necrosis Factor (TNF) Inhibitors
• Interleukin Inhibitors
• Other Biologics
• 6.7. Global Psoriatic Arthritis Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Topical Treatments
• Janus Kinase (JAK) Inhibitors

7. Psoriatic Arthritis Treatment Market Regional And Country Analysis

• 7.1. Global Psoriatic Arthritis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Psoriatic Arthritis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Psoriatic Arthritis Treatment Market

• 8.1. Asia-Pacific Psoriatic Arthritis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Psoriatic Arthritis Treatment Market

• 9.1. China Psoriatic Arthritis Treatment Market Overview
• 9.2. China Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Psoriatic Arthritis Treatment Market

• 10.1. India Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Psoriatic Arthritis Treatment Market

• 11.1. Japan Psoriatic Arthritis Treatment Market Overview
• 11.2. Japan Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Psoriatic Arthritis Treatment Market

• 12.1. Australia Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Psoriatic Arthritis Treatment Market

• 13.1. Indonesia Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Psoriatic Arthritis Treatment Market

• 14.1. South Korea Psoriatic Arthritis Treatment Market Overview
• 14.2. South Korea Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Psoriatic Arthritis Treatment Market

• 15.1. Western Europe Psoriatic Arthritis Treatment Market Overview
• 15.2. Western Europe Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Psoriatic Arthritis Treatment Market

• 16.1. UK Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Psoriatic Arthritis Treatment Market

• 17.1. Germany Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Psoriatic Arthritis Treatment Market

• 18.1. France Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Psoriatic Arthritis Treatment Market

• 19.1. Italy Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Psoriatic Arthritis Treatment Market

• 20.1. Spain Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Psoriatic Arthritis Treatment Market

• 21.1. Eastern Europe Psoriatic Arthritis Treatment Market Overview
• 21.2. Eastern Europe Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Psoriatic Arthritis Treatment Market

• 22.1. Russia Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Psoriatic Arthritis Treatment Market

• 23.1. North America Psoriatic Arthritis Treatment Market Overview
• 23.2. North America Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Psoriatic Arthritis Treatment Market

• 24.1. USA Psoriatic Arthritis Treatment Market Overview
• 24.2. USA Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Psoriatic Arthritis Treatment Market

• 25.1. Canada Psoriatic Arthritis Treatment Market Overview
• 25.2. Canada Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Psoriatic Arthritis Treatment Market

• 26.1. South America Psoriatic Arthritis Treatment Market Overview
• 26.2. South America Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Psoriatic Arthritis Treatment Market

• 27.1. Brazil Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Psoriatic Arthritis Treatment Market

• 28.1. Middle East Psoriatic Arthritis Treatment Market Overview
• 28.2. Middle East Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Psoriatic Arthritis Treatment Market

• 29.1. Africa Psoriatic Arthritis Treatment Market Overview
• 29.2. Africa Psoriatic Arthritis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Psoriatic Arthritis Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Psoriatic Arthritis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Psoriatic Arthritis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Psoriatic Arthritis Treatment Market Competitive Landscape
• 30.2. Psoriatic Arthritis Treatment Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Amgen Astellas BioPharma K.K. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Psoriatic Arthritis Treatment Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. Eli Lilly and Company
• 31.3. Pfizer Inc.
• 31.4. CB Biosciences Inc.
• 31.5. Hoffmann-La Roche Ltd.
• 31.6. Merck & Co. Inc.
• 31.7. AstraZeneca plc
• 31.8. Sanofi SA
• 31.9. Otsuka Pharmaceutical Co. Ltd.
• 31.10. Sumitomo Dainippon Pharma Co. Ltd.
• 31.11. Bayer AG
• 31.12. Abbott Laboratories
• 31.13. Eisai Inc.
• 31.14. Janssen Pharmaceuticals Inc.
• 31.15. Bausch Health Companies Inc.

32. Global Psoriatic Arthritis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Psoriatic Arthritis Treatment Market

34. Recent Developments In The Psoriatic Arthritis Treatment Market

35. Psoriatic Arthritis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Psoriatic Arthritis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Psoriatic Arthritis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Psoriatic Arthritis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer